Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Clarksterh	3/7/2005 4:14:48 PM
	Read Replies (1) of 946

Probably the most interesting items (to me) in the cc were: 1) The fact that the two arms were not balanced. When a prospectively defined Cox analysis was performed to account for the imbalance Xyotax was highly stat sig for survival. (The implication of this is that the docs found a way around the stratification and sicker patients were more likely to get Xyotax - although CTI didn't explicitly say that they stratified for the things in the Cox Regression) 2) US, Canada and WE all showed more cycles for Xyotax. By exclusion, EE did not - they showed equal. Message - Need to control the trial. And that means doing it somewhere where you can maintain the needed control. Clark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next